DOCSLIB.ORG

1 Atorvastatin Calcium 2 Sodium Chloride 3 Clopidogrel 4 Glucose 5

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Atorvastatin Calcium 2 Sodium Chloride 3 Clopidogrel 4 Glucose 5 1 Atorvastatin calcium 2 Sodium chloride 3 Clopidogrel 4 Glucose 5 Acarbose 6 Cefoperazone sodium and sulbactam sodium 7 Budesonide 8 Entecavir 9 Piperacillin sodium and tazobactam sodium 10 Omeprazole sodium 11 Pantoprazole sodium 12 Amlodipine 13 Danshen ligustrazine 14 Nitrate benidipine 15 Oxiracetam 16 Ceftazidime 17 Alprostadil 18 Levofloxacin 19 Ganglioside sodium 20 Edaravone 21 Rosuvastatin calcium 22 L-Amlodipine 23 Meropenem 24 Cefuroxime sodium 25 Metin 26 Cefmetazole sodium 27 Phosphate creatine 28 Ambroxol 29 Rabeira sodium azole 30 Calf blood deproteinized extract 31 Cefoxitin sodium 32 Pemetrexed disodium 33 Moxifloxacin 34 Piperacillin sodium sulbactam sodium 35 Propofol 36 Pinsartan 37 Tige 38 Vinpocetine 39 Cerebroside carnosine 40 Laoxycephalosporin 41 Hemagglutinin 42 Cefazolin sodium 43 Docetaxel 44 Ceftriaxone sodium 45 Lansoprazole 46 Olanzapine 47 Irbesartan 48 Oseltamivir 49 Peritoneal dialysis 50 Cefixime 51 Doxofylline 52 Mezlocillin sodium and sulbactam sodium 53 Sevoflurane 54 Iohexol 55 Capecitabine 56 Amoxicillin and clavulanate potassium 57 Flurbiprofen 58 Low molecular weight heparin calcium 59 Cefotiam 60 Tanshinone IIA sodium sulfonate 61 Levocarnitine 62 Cefmetazole sodium 63 Oxaliplatin 64 Troxerutin hydrolysate 65 Aspirin 66 Alanyl glutamine 67 Montelus special sodium 68 Compound amino acid (AA) 69 Irbesartan hydrochlorothiazide 70 Reduced glutathione 71 Calcium carbonate D 72 Cefdinir 73 Imipenem and cilastatin sodium 74 Recombinant insulin glargine 75 Ribonucleic acid 76 Glucosamine 77 Tacrolimus 78 Metoprolol 79 Cephalosporin sodium thyroxine 80 Iodixanol 81 Paclitaxel liposome 82 Gastrodin 83 Dexmedetomidine 84 Aoxin 85 Rituximab 86 Magnesium isoglycyrrhizinate 87 Ornidazole 88 Amoxicillin potassium clavulanate 89 Octreotide 90 Invert sugar electrolyte 91 Leuprolide 92 Butylphthalide 93 Protamine biosynthetic human insulin 94 Cefoperazone sodium tazobactam sodium 95 Cinepazide 96 Glimepiride 97 Losartan potassium 98 Tropisetron 99 Methyl cobalt amine 100 Cefaclor 101 Cisatracurium benzene sulfonate 102 Mycophenolate mofetil 103 Cefditoren 104 Octapeptide 105 Voriconazole 106 Methylprednisolone 107 Gemcitabine 108 Lugua polypeptide 109 Somatostatin 110 Compound coenzyme 111 Compound α-keto acid 112 Dezocine 113 Butyl phenol 114 Isosorbide mononitrate 115 Goserelin 116 Other dosage forms of goserelin 117 Cefamandole sodium 118 Etamycin 119 Thymopentin 120 Azithromycin 121 Cefotaxime sodium and sulbactam sodium 122 Thymosin 123 Azithromycin 124 Trastuzumab 125 Calcitriol 126 Yanruining 127 Cerebroprotein hydrolysate 128 Citicoline sodium 129 Cefodizime sodium 130 Lipoic acid 131 Budesonide oterol 132 Pantoprazole sodium 133 Loversol 134 Repaglinide 135 Felodipine 136 Bone melon extract 137 Temozolomide 138 Omeprazole 139 Clindamycin 140 Citicoline sodium 141 Sulbenicillin sodium 142 Cefminox sodium 143 Letrozole 144 Zoledronic acid 145 Hydroxyethyl starch 146 Cefuroxime axetil 147 Compound glycyrrhizin 148 Ursodeoxycholic acid 149 Escitalopram 150 Gliclazide 151 Trimetazidine 152 Ubenimex 153 Cefprozil 154 Simvastatin 155 Ginkgo leaf extract 156 Irinotecan 157 Rivaroxaban 158 Imatinib 159 Ceftezole sodium 160 Risperidone 161 Tamsulosin 162 Paclitaxel 163 Voriconazole 164 Amoxicillin 165 Dibutyryl cyclic adenosine monophosphate 166 Loperamide 167 Medium/long-chain fatty emulsion (C~) 168 Nalmefene 169 Cefmenoxime 170 Enoxaparin sodium 171 Telmisartan 172 Cyclosporine 173 Aescin sodium 174 Desloratadine citrate 175 Fat-soluble vitamin 176 Clarithromycin 177 Levofloxacin 178 Losartan potassium hydrochlorothiazide 179 Ulinastatin 180 Tetramethylpyrazine 181 Polyene phosphatidylcholine 182 Mezlocillin Sodium 183 Palonosetron 184 Biapenem 185 Phloroglucinol 186 Fat emulsion/amino acid/glucose 187 Adenosyl amine 188 Finasteride 189 Quetiapine 190 Meglumine cyclic adenosine 191 Triptorelin 192 Sodium hyaluronate 193 Rabeprazole sodium 194 Isopropyl tropylium bromide 195 Pitavastatin calcium 196 Esomeprazole magnesium 197 Acetyl glutamine 198 Ozagrel sodium 199 Doxorubicin liposome 200 Salmeterol xinafoate 201 Caspofungin 202 Salbutamol 203 Candesartan cilexetil 204 Oxiracetam 205 Insulin aspart 206 Benazepril 207 Ginkgo damo 208 Epirubicin 209 Piracetam 210 Multivitamins 211 Aripiprazole 212 Terbutaline 213 Bicalutamide 214 Spleen polypeptide 215 Cyclophosphamide 216 Glipizide 217 Low molecular heparin sodium 218 Compound polyethylene glycol electrolyte 219 Lansoprazole 220 Bisoprolol 221 Vancomycin 222 Calf spleen extract 223 Lobaplatin 224 Tiotropium bromide 225 Flupentixol and melitracen 226 Magnesium hydroxide 227 Ornithine aspartate 228 Glucose sodium chloride 229 Compound glycyrrhizinate monoamine 230 Ibuprofen 231 Insulin detemir 232 Sodium valproate 233 Placental polypeptide 234 Ropivacaine 235 Dydrogesterone 236 Mosapride 237 Pediatric amino acid 238 Arabinoside monophosphate 239 Bicyclic alcohol 240 Sertraline 241 Compound glycyrrhizin 242 Compound osteotide 243 Carboprost tromethamine 244 Clindamycin Palmitate 245 Linezolid 246 Lactulose 247 Puerarin 248 Aztreonam 249 Lactulose 250 Fructose 251 Ceftriaxone sodium tazobactam sodium 252 Adenosyl methionine 253 Donepezil 254 Deoxynucleotide sodium 255 Paroxetine 256 Gefitinib 257 Anastrozole 258 Spleen aminopeptide 259 Esomeprazole sodium 260 Thiazolidinediones 261 Protamine zinc recombinant human insulin (/) 262 Venlafaxine 263 Celecoxib 264 Chloroquine 265 Mannan peptide 266 Acetylcysteine 267 Ambroxol sorafenib 268 Sorafenib 269 Progesterone 270 Epalrestat 271 Compound diisopropylamine dichloroacetate 272 Compound brain peptide ganglioside 273 Icotinib 274 Sodium hyaluronate 275 Milrinone 276 Sodium potassium magnesium calcium glucose 277 Parecoxib sodium 278 Calcium dobesilate 279 Compound plaque chelate 280 Progesterone 281 Olmesartan medoxomil 282 Propatamol hydrochloride 283 Tigecycline 284 Levofloxacin 285 Oxytocin 286 Norepinephrine 287 Vitamin C 288 Gadobenate dimeglumine 289 Flurbiprofen 290 Mixed sugar electrolyte 291 Duloxetine 292 Diclofenac sodium 293 Omeprazole 294 Voglibose 295 Sucrose iron 296 Lopamidol 297 Three-dimensional B 298 Heparin sodium 299 Enteral nutrition suspension (TPP) 300 Alfacalcidol 301 Febuxostat 302 Compound methoxynamine 303 Torsemide 304 Adefovir dipivoxil 305 Dolasetron 306 Pidotimod 307 Ondansetron 308 Naloxone hydrochloride 309 Pravastatin sodium 310 Mometasone 311 Exemestane 312 Ticagrelor 313 Compound lactobacillus acidophilus 314 Ketorolac tromethamine 315 Roxithromycin 316 Urinary follicle stimulating hormone 317 Levodopa/benserazide 318 Nedaplatin 319 Amisulpride 320 Aamlodipine 321 Sodium valproate 322 Multi-trace element 323 Isosorbide mononitrate 324 Terbutaline 325 Loratadine 326 Moxifloxican hydrochloride 327 Compound digestive enzyme 328 Sitagliptin 329 Vitamin D 330 Urapidil 331 Gas cinnarizine 332 Compound vitamin 333 Beraprost 334 Cefepime 335 Mesalazine 336 Lentinan 337 Mannitol 338 Cefoxitin sodium 339 Tranexamic acid 340 Cubicin 341 Leflunomide 342 Invert sugar 343 Mecobalamin 344 Acetylcysteine 345 Fasudil 346 Plague 347 Perindopril 348 Potassium chloride 349 Porcine Alphaline 350 Bortezomib 351 Lamivudine 352 Compound licorice 353 Structured fat emulsion ( C-) 354 Fat emulsion (C-) 355 Bozhi glycopeptide 356 Carrosol sodium 357 Elemene 358 Compound amino acid (AA) 359 Da cronin 360 Polysaccharide iron 361 Silymarin 362 Compound cefaclor 363 Enalapril 364 Teicoplanin 365 Ampicillin 366 Compound amino acid 367 Dextropropimide 368 Recombinant human type II tumor necrosis factor receptor-antibody fusion 369 Domperidone 370 Fat-soluble vitamin (II) / water-soluble vitamin 371 Alocillin sodium 372 Sarcosine 373 Enalapril folic acid 374 Calcium gluconate 375 Lapatinib 376 Fluconazole 377 Levothyroxine sodium 378 Pancreatic kininogenase 379 Glycerol fructose 380 Valsartan hydrochlorothiazide 381 Idebenone 382 Rebamipide 383 Rocuronium bromide 384 Nicergoline 385 Insulin aspart 386 Calcium acetate 387 Salbutamol 388 Profenbeine 389 Potassium aspartate 390 Desloratadine 391 Etomidate 392 Tirofiban 393 Levetiracetam 394 Licorice dizinc acid 395 Compound tripotide 396 Omeprazole Magnesium 397 Nimodipine 398 Ratitrexed 399 Tetrandrine 400 Oxcarbazepine 401 Diosmin 402 Vitamin B 403 Polyene phosphatidylcholine 404 Enteral nutrition emulsion (TPF-D) 405 Bevacizumab 406 Prapofren 407 Amoxicillin sodium and sulbactam sodium 408 Compound nystatin 409 Enteral nutrition emulsion (TPP-T) 410 Indapamide 411 Prednisolone 412 Cloxacillin sodium 413 Loxoprofen sodium 414 Compound reserpine and triamterene 415 Enteral nutrition suspension (SP) 416 Ibandronate sodium 417 Sufentanil 418 Pediatric paracetamol 419 Fibrinolytic enzyme 420 Potassium magnesium aspartate 421 Argatroban 422 Lidocaine 423 Itraconazole 424 Vitamin AD 425 Deacetyl hairin 426 Mirtazapine 427 Ferrous succinate 428 Cetirizine 429 Fluorouracil 430 Protamine zinc recombinant insulin lispro (R) 431 Ferric protein peroxide 432 Polygelatin peptide 433 Fish Oil Fat Emulsion 434 Irecoxib 435 Dopamine 436 Levoornidazole 437 Fenofibrate 438 Vitamin B 439 Esmolol 440 Fosinopril 441 Amlodipine atorvastatin calcium 442 Compound paracetamol 443 Succinyl gelatin 444 Telbivudine 445 Roxatidine 446 Rifampicin 447 Apricot 448 Pegylated interferon a-a 449 Abiraterone 450 Diclofenac sodium 451 Compound potassium hydrogen phosphate 452 Mycophenolate sodium 453 Tobramycin dexamethasone 454 Lixisena 455 Protamine biosynthesis human insulin (R) 456 Paracetamol and oxycodone 457 Amifostine 458 Dalteparin sodium 459 Ambroxol 460 Esomeprazole 461 Reduced
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • Thymic Peptides and Preparations: an Update
    ¡ Archivum Immunologiae et Therapiae Experimentalis, 1999, 47¢ , 77–82 £ PL ISSN 0004-069X Review Thymic Peptides and Preparations: an Update ¤ O. J. Cordero et al.: Thymic Peptides ¦ ¨ § OSCAR J. CORDERO, A¥ LICIA PIÑEIRO and MONTSERRAT NOGUEIRA Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain Abstract. The possibilities of thymic peptides in human therapy are still being described. Here, we focus on their © general characteristics and on recent advances in this area. Key words: thymus; thymic peptides; preclinical investigation; therapeutic use; clinical trials. Thymic peptides, as well as a variety of other purified from porcine and human serum and from calf modulators (IL-1, IL-3, IL-6, GM-CSF) and cell-cell thymus, and named “facteur thymique serique”11. interactions, regulate the process known as thymic se- According to the classical criteria, TH is the unique lection by which pro-thymocytes become mature and peptide that can be recognized as a hormone. Its secre- functional T cells. tion by a subpopulation of thymic epithelial cells (TEC) Several polypeptides have been extracted, mainly is controlled by a pleiotropic mechanism involving its from young calves, and some of them have been suc- own levels and those of prolactine (PRL), growth hor- cessfully isolated and prepared synthetically (Fig. 1). mone (GH) through insulin growth factor 1 (IGF-1) se- The precise role of much of these factors purported to cretion, adrenocorticotropin (ACTH), thyroxin (T4), β- have intrathymic effects is still unknown, although endorphin and β-leukencephalin and IL-1α and β8. many of these compounds exhibit immunobiological Furthermore, reciprocal regulatory actions on the activity.
    [Show full text]
  • Biological Values of Cultivated Mushrooms – a Review
    Acta Alimentaria, Vol. 48 (2), pp. 229–240 (2019) DOI: 10.1556/066.2019.48.2.11 BIOLOGICAL VALUES OF CULTIVATED MUSHROOMS – A REVIEW J. VETTER* Department of Botany, University of Veterinary Sciences, H-1077 Budapest, Rottenbiller u. 50. Hungary (Received: 3 July 2018; accepted: 11 October 2018) Cultivated mushrooms are not only valuable foods of our age (functional foods) but contain certain benefi cial chemical components (high level of K and P, very low content of Na, considerable quantities of some microelements, high and valuable protein but low fat contents). Some cultivated mushrooms have anti-carcinogenic effects caused fi rst of all by polysaccharides (Lentinan: Lentinula edodes) and by triterpenoids (ganoderic acids: Ganoderma lucidum or unsaturated fatty acids: linoleic, linolenic acids); antidiabetic effects, which can improve the sugar metabolism of patients (Coprinus comatus, Ganoderma lucidum, Agaricus bisporus); anti-microbial effects, caused partly by smaller triterpenoids or by higher molecules, i.e. by direct or indirect effects: via stimulation of the immune system. Certain mushrooms have antioxidant effects, provided mostly by higher radical scavenging activity of phenolic (fl avonoid) components. The chemical composition and its biological effects form together the biological values of the cultivated mushrooms. The following review would like to summarize the most important facts of this topic. Keywords: cultivated mushrooms, chemical components, nutritional values, anti-carcinogenic, antidiabetic, antimicrobial, antioxidant effects Mushrooms have been consumed since earliest historical times; Greeks believed that mushrooms provided strength for warriors, the Romans named them as the “Food of the Gods”. In countries of the Orient, certain mushrooms were believed “elixir of life” etc.
    [Show full text]
  • Shiitake Mushroom: a Tool of Medicine
    REVIEW ARTICLE Shiitake Mushroom: A Tool of Medicine Taufiqur Rahman1, MBK Choudhury2 1National Mushroom Development Project, Savar, Dhaka 2Directorate General of Health Services, Dhaka ABSTRACT Medicinal mushrooms have an established history of use in traditional oriental therapies. Contemporary research has validated and documented much of the ancient knowledge. Over the last three decades, the interdisciplinary fields of science that study medicinal mushrooms has sprung up and has increasingly demonstrated the potent and unique properties of compounds extracted from a range of species. Currently, the field is being developed into a very fruitful area. Modern clinical practice in Japan, China, Korea and other Asian countries rely on mushroom-derived preparations. Mushrooms have been studied for nutritional and medical purposes for its various potential anti-tumoral and immunomodulatory componests like polysaccharides that have been identified. For medical purposes, mushrooms have been consumed to prevent cancer and cardiac diseases, to improve blood circulation and to reduce blood cholesterol level. Some of these mushrooms have also been used for the treatment of physical and emotional stress, osteoporosis, gastric ulcers and chronic hepatitis, for the improvement of the quality of life of patients with diabetes and especially for the stimulation of immunity. Shiitake has a history of medicinal uses. The mushroom is used as anticarcinogenic, anti- inflammatory, antioxidant, antifungal, antibacterial, antiviral as well as antithrombotic in cardiovascular disorders. This article has been written to throw some light on Shiitake mushroom which has many nutritional values. Many Shiitake preparations came in market containing the active ingredients which can replace many other marketed synthetic medicines and may prove to have promising results with fewer side effects.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Viewer Token: Utgzgyeiftozbgp)
    BASIC RESEARCH www.jasn.org A High-Throughput Screen Identifies DYRK1A Inhibitor ID-8 that Stimulates Human Kidney Tubular Epithelial Cell Proliferation Maria B. Monteiro,1 Susanne Ramm,1,2 Vidya Chandrasekaran,1 Sarah A. Boswell,1 Elijah J. Weber,3 Kevin A. Lidberg,3 Edward J. Kelly,3 and Vishal S. Vaidya1,2,4 1Harvard Program in Therapeutic Science, Harvard Medical School Laboratory of Systems Pharmacology, Boston, Massachusetts; 2Renal Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts; 3Department of Pharmaceutics, University of Washington, Seattle, Washington; and 4Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts ABSTRACT Background The death of epithelial cells in the proximal tubules is thought to be the primary cause of AKI, but epithelial cells that survive kidney injury have a remarkable ability to proliferate. Because proximal tubular epithelial cells play a predominant role in kidney regeneration after damage, a potential approach to treat AKI is to discover regenerative therapeutics capable of stimulating proliferation of these cells. Methods We conducted a high-throughput phenotypic screen using 1902 biologically active compounds to identify new molecules that promote proliferation of primary human proximal tubular epithelial cells in vitro. Results The primary screen identified 129 compounds that stimulated tubular epithelial cell proliferation. A secondary screen against these compounds over a range of four doses confirmed that eight resulted in a significant increase in cell number and incorporation of the modified thymidine analog EdU (indicating actively proliferating cells), compared with control conditions. These eight compounds also stimulated tubular cell proliferation in vitro after damage induced by hypoxia, cadmium chloride, cyclosporin A, or polymyxin B.
    [Show full text]
  • Thymopentin and Splenopentin As Immunomodulators Current Stutus
    Immunologic Research 1998;17/3:345-368 Thymopentin and Splenopentin as Immunomodulators Current Stutus 1Department of Immunology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, India. 2Division of Biopolymers, Central Drug Research Institute, Lucknow, India. 3Department of Microbiology, RML Awadh University, Faizabad, India. Abstract Key Words Splenopentin (SP-5, Arg-Lys-Glu-Val-Tyr) and thymopentin (TP-5, Immunomodulation Arg-Lys-Asp-Val-Tyr) are synthetic immunomodulating peptides Splenin corresponding to the region 32-34 of a splenic product called splenin Splenopentin (SP) and the thymic hormone thymopoietin (TP), respectively. TP Thymopoietin was originally isolated as a 5-kDa (49-amino acids) protein from Thymopentin bovine thymus while studying effects of the thymic extracts on neuro- muscular transmission and was subsequently observed to affect T cell differentiation and function. TP I and II are two closely related polypeptides isolated from bovine thymus. A radioimmunoassay for TP revealed a crossreaction with a product found in spleen and lymph node. This product, named splenin, differs from TP only in position 34, aspartic acid for bovine TP and glutamic acid for bovine splenin and it was called TP III as well. Synthetic pentapeptides (TP-5) and (SP-5), reproduce the biological activities of TP and SP, respectively. It is now evident that various forms of TPs were created by proteolytic cleavage of larger proteins during isolation, cDNA clones have been isolated for three alternatively spliced mRNAs that encodes three distinct human T cell TPs. The immunomodulatory properties of TP, SP, TP-5, SP-5 and some of their synthetic analogs reported in the literature have been briefly reviewed.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Low Molecular Weight Heparins and Heparinoids
    NEW DRUGS, OLD DRUGS NEW DRUGS, OLD DRUGS Low molecular weight heparins and heparinoids John W Eikelboom and Graeme J Hankey UNFRACTIONATED HEPARIN has been used in clinical ABSTRACT practice for more than 50 years and is established as an effective parenteral anticoagulant for the prevention and ■ Several low molecular weight (LMW) heparin treatment of various thrombotic disorders. However, low preparations, including dalteparin, enoxaparin and molecularThe Medical weight Journal (LMW) of heparinsAustralia haveISSN: recently 0025-729X emerged 7 October as nadroparin, as well as the heparinoid danaparoid sodium, more2002 convenient, 177 6 379-383 safe and effective alternatives to unfrac- are approved for use in Australia. 1 tionated©The heparin Medical (BoxJournal 1). of AustraliaIn Australia, 2002 wwwLMW.mja.com.au heparins are ■ LMW heparins are replacing unfractionated heparin for replacingNew Drugs,unfractionated Old Drugs heparin for preventing and treating the prevention and treatment of venous thromboembolism venous thromboembolism and for the initial treatment of and the treatment of non-ST-segment-elevation acute unstable acute coronary syndromes. The LMW heparinoid coronary syndromes. danaparoid sodium is widely used to treat immune heparin- ■ induced thrombocytopenia. The advantages of LMW heparins over unfractionated heparin include a longer half-life (allowing once-daily or twice-daily subcutaneous dosing), high bioavailability and Limitations of unfractionated heparin predictable anticoagulant response (avoiding the need
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Prebiotics: a Novel Approach to Treat Hepatocellular Carcinoma
    Hindawi Canadian Journal of Gastroenterology and Hepatology Volume 2017, Article ID 6238106, 11 pages https://doi.org/10.1155/2017/6238106 Review Article Prebiotics: A Novel Approach to Treat Hepatocellular Carcinoma Naz Fatima,1 Tasleem Akhtar,1 and Nadeem Sheikh1,2 1 Cell and Molecular Biology Lab, Department of Zoology, University of the Punjab, Q-A Campus, Lahore 54590, Pakistan 2Cell and Applied Molecular Biology (CAMB), University of the Punjab, Q-A Campus, Lahore 54590, Pakistan Correspondence should be addressed to Nadeem Sheikh; [email protected] Received 13 February 2017; Accepted 19 April 2017; Published 10 May 2017 Academic Editor: JoseL.Mauriz´ Copyright © 2017 Naz Fatima et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Hepatocellular carcinoma is one of the fatal malignancies and is considered as the third leading cause of death. Mutations, genetic modifications, dietary aflatoxins, or impairments in the regulation of oncogenic pathways may bring about liver cancer.An effective barrier against hepatotoxins is offered by gut-liver axis as a change in gut permeability and expanded translocation of lipopolysaccharides triggers the activation of Toll-like receptors which stimulate the process of hepatocarcinogenesis. Prebiotics, nondigestible oligosaccharides, have a pivotal role to play when it comes to inducing an antitumor effect. A healthy gut flora balance is imperative to downregulation of inflammatory cytokines and reducing lipopolysaccharides induced endotoxemia, thus inducing the antitumor effect. 1. Introduction pathway are deregulated as well, but on a marginal scale.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]